Radiochemical studies relevant to 86Y production via 86Sr(p,n)86Y for PET imaging

Sadeghi, Mahdi; Aboudzadeh, Mohammadreza; Zali, A.; Mirzaii, M.; Bolourinovin, Fatemeh

doi:10.1016/j.apradiso.2008.08.017

Cited by 29 publications

(18 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The originally used highly-enriched 86 SrCO 3 as the target material [16] was employed in most of the later works, as well [26,27,28,29,30,31,32,33,34,35,36]. In one case, 86 SrO was also used [31].…”

Section: Production Methodologiesmentioning

confidence: 99%

“…In another system [32], besides the water-cooling of the target at the back, chilled He cooling in front of the target was applied, and irradiation currents of up to 15 μA of 11-MeV protons could be used. In yet another system [27,31,35,36], the target material was irradiated with 15-MeV protons at an inclined angle between 6° and 15° in a target holder cooled by a jet of cooling water across its back. A beam current of 10 μA was used [27], but the target may withstand higher currents [31,35,36], at least for short irradiations.…”

Section: Production Methodologiesmentioning

confidence: 99%

“…In fact, this impurity should be vanishingly small because the main contributing reaction 86 Sr(p,γ) 87m,g Y is expected to have a very small cross-section [24,25]. However, since the enriched 86 Sr target used had an isotopic enrichment of only 96.4% [16,26,27,28,29,30,31,32,33,34,35,36], the small amount of 87 Sr (1.33%) present in the target contributed to the formation of the 87m,g Y impurity via the 87 Sr(p,n)-reaction. The same applies to the very small amount of the 88 Y impurity.…”

Section: Nuclear Datamentioning

confidence: 99%

See 2 more Smart Citations

The Beginning and Development of the Theranostic Approach in Nuclear Medicine, as Exemplified by the Radionuclide Pair 86Y and 90Y

2017

View full text Add to dashboard Cite

In the context of radiopharmacy and molecular imaging, the concept of theranostics entails a therapy-accompanying diagnosis with the aim of a patient-specific treatment. Using the adequate diagnostic radiopharmaceutical, the disease and the state of the disease are verified for an individual patient. The other way around, it verifies that the radiopharmaceutical in hand represents a target-specific and selective molecule: the “best one” for that individual patient. Transforming diagnostic imaging into quantitative dosimetric information, the optimum radioactivity (expressed in maximum radiation dose to the target tissue and tolerable dose to healthy organs) of the adequate radiotherapeutical is applied to that individual patient. This theranostic approach in nuclear medicine is traced back to the first use of the radionuclide pair 86Y/90Y, which allowed a combination of PET and internal radiotherapy. Whereas the β-emitting therapeutic radionuclide 90Y (t½ = 2.7 d) had been available for a long time via the 90Sr/90Y generator system, the β+ emitter 86Y (t½ = 14.7 h) had to be developed for medical application. A brief outline of the various aspects of radiochemical and nuclear development work (nuclear data, cyclotron irradiation, chemical processing, quality control, etc.) is given. In parallel, the paper discusses the methodology introduced to quantify molecular imaging of 86Y-labelled compounds in terms of multiple and long-term PET recordings. It highlights the ultimate goal of radiotheranostics, namely to extract the radiation dose of the analogue 90Y-labelled compound in terms of mGy or mSv per MBq 90Y injected. Finally, the current and possible future development of theranostic approaches based on different PET and therapy nuclides is discussed.

show abstract

Section: Production Methodologiesmentioning

confidence: 99%

Section: Production Methodologiesmentioning

confidence: 99%

Section: Nuclear Datamentioning

confidence: 99%

See 1 more Smart Citation

The Beginning and Development of the Theranostic Approach in Nuclear Medicine, as Exemplified by the Radionuclide Pair 86Y and 90Y

2017

View full text Add to dashboard Cite

show abstract

“…The possible production routes for Y-86 that have been considered are as follows: 86 Sr( p, n) 86 Y, E p = 14.5 → 11.0 MeV; nat Rb( 3 He, xn), E 3 He = 24 → 12 MeV; 88 Sr( p, 3n) 86 Y, E p = 45 → 37 MeV; and 90 Zr( p, 2 p3n) 86 Y, E p = 40 → 30 MeV [10,11,16,17]. Out of these, it seems that the best method is the 86 Sr( p, n) 86 Y reaction, but it requires enriched 86 Sr which is rather expensive and economy requires its recovery and reuse [10,17].…”

Section: Yttrium-86mentioning

confidence: 99%

Paving the way to personalized medicine: production of some theragnostic radionuclides at Brookhaven National Laboratory

Srivastava¹

2011

Ract

View full text Add to dashboard Cite

This paper introduces a relatively novel paradigm that involves specific individual radionuclides or radionuclide pairs that have emissions that allow pre-therapy low-dose imaging plus higher-dose therapy in the same patient. We have made an attempt to sort out and organize a number of such theragnostic radionuclides and radionuclide pairs that may potentially bring us closer to the age-long dream of personalized medicine for performing tailored low-dose molecular imaging (SPECT/CT or PET/CT) to provide the necessary pre-therapy information on biodistribution, dosimetry, the limiting or critical organ or tissue, and the maximum tolerated dose (MTD), etc. If the imaging results then warrant it, it would be possible to perform higher-dose targeted molecular therapy in the same patient with the same radiopharmaceutical. A major problem that remains yet to be fully resolved is the lack of availability, in sufficient quantities, of a majority of the best candidate theragnostic radionuclides in a no-carrier-added (NCA) form. A brief description of the recently developed new or modified methods at BNL for the production of four theragnostic radionuclides, whose nuclear, physical, and chemical characteristics seem to show great promise for personalized cancer therapy are described.

show abstract

“…5,13,14 Recovered Sr-86 will contain radioactive Sr-85 after first irradiation if the proton energy is more than 14 MeV, which would mean that hot cell target assembly will be required. At BNL, we have designed such a target, both halves of which are aluminum for better conductivity, head screws are large enough for remote manipulator handling and silver-coated stainless steel C-rings are used to provide adequate seals.…”

Section: Yttrium-86mentioning

confidence: 99%

A Bridge not too Far: Personalized Medicine with the use of Theragnostic Radiopharmaceuticals

Srivastava¹

2013

Journal of Postgraduate Medicine, Education and Research

View full text Add to dashboard Cite

This article deals primarily with the selection criteria, production, and the nuclear, physical, and chemical properties of certain dual-purpose radionuclides, including those that are currently being used, or studied and evaluated, and those that warrant future investigations. Various scientific and practical issues related to the production and availability of these radionuclides is briefly addressed. At brookhaven national laboratory (BNL), we have developed a paradigm that involves specific individual 'dual-purpose' radionuclides or radionuclide pairs with emissions suitable for both imaging and therapy, and which when molecularly (selectively) targeted using appropriate carriers, would allow pre-therapy low-dose imaging plus higher-dose therapy in the same patient. We have made an attempt to sort out and organize a number of such theragnostic radionuclides and radionuclide pairs that may thus potentially bring us closer to the age-long dream of personalized medicine for performing tailored low-dose molecular imaging (SPECT/CT or PET/CT) to provide the necessary pretherapy information on biodistribution, dosimetry, the limiting or critical organ or tissue, and the maximum tolerated dose (MTD), etc., followed by performing higher-dose targeted molecular therapy in the same patient with the same radiopharmaceutical. As an example, our preclinical and clinical studies with the theragnostic radionuclide Sn-117m are covered in somewhat greater detail.A troublesome problem that remains yet to be fully resolved is the lack of availability, in sufficient quantities and at reasonable cost, of a majority of the best candidate theragnostic radionuclides in a no-carrier-added (NCA) form. In this regard, a summary description of recently developed new or modified methods at BNL for the production of five theragnostic radionuclide/radionuclide pair items, whose nuclear, physical, and chemical characteristics seem to show promise for therapeutic oncology and for treating other disorders that respond to radionuclide therapy, is provided.

show abstract

Radiochemical studies relevant to 86Y production via 86Sr(p,n)86Y for PET imaging

Cited by 29 publications

References 19 publications

The Beginning and Development of the Theranostic Approach in Nuclear Medicine, as Exemplified by the Radionuclide Pair 86Y and 90Y

The Beginning and Development of the Theranostic Approach in Nuclear Medicine, as Exemplified by the Radionuclide Pair 86Y and 90Y

Paving the way to personalized medicine: production of some theragnostic radionuclides at Brookhaven National Laboratory

A Bridge not too Far: Personalized Medicine with the use of Theragnostic Radiopharmaceuticals

Contact Info

Product

Resources

About